TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05102162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime, Meropenem, or Piperacillin/Tazobactam
Description: A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime, Meropenem, or Piperacillin/Tazobactam
Description: A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
Study: NCT06116357

Intervention type: DEVICE
Group type: OTHER
Intervention: External Ultrasonic Micro-bubble
Description: The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
Study: NCT04828993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis meglumine
Description: Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
Study: NCT05747742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RLRL device
Description: Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL device
Description: Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
Study: NCT05030207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-time Gated 4DCT
Description: Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional 4DCT
Description: Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
Study: NCT06519812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Intrarenal Surgery and percutaneous nephrolithotomy
Description: A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Intrarenal Surgery and percutaneous nephrolithotomy
Description: A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
Study: NCT04807933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability Biofeedback [HRV-BFB]
Description: BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
Study: NCT05956899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: IV ondansetron 0.15mg/kg at the start of wound closure
Study: NCT06137586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of GIP[1-42], GIP[1-30] or placebo
Description: This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
Study: NCT04642391

Intervention type: DRUG
Intervention: Cosyntropin
Description: Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis

Intervention type: DRUG
Intervention: Cosyntropin
Description: Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
Study: NCT04150419

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 (control group)
Description: Neutral attentional training (control group).
Study: NCT04486378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457 intravenous (IV)
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457 intravenous (IV)
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457 intravenous (IV)
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457 intravenous (IV)
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Observational group (no intervention)
Description: watchful waiting
Study: NCT05789394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adipose-derived Mesenchymal Stem Cells
Description: Receive IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: Undergo craniotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir Tap
Description: Undergo Ommaya reservoir placement for collection of CSF
Study: NCT05952570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral protein nutritional supplement (Fresubin protein powder)
Description: 50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine nutrition regimen
Description: 50 patients will receive a routine nutrition regimen for 3 months. (control group)
Study: NCT06010342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL118 Capsule
Description: Oral administration
Study: NCT05897411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmasking previous conditioning procedure
Description: An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No unmasking of previous conditioning
Description: An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
Study: NCT05733052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyester suture
Description: A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
Study: NCT05730413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
Study: NCT05971693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator
Description: Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
Study: NCT05609435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REASSURE
Description: REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
Study: NCT04451499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
Study: NCT05881161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence self-efficacy-enhancing exercise
Description: This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med-Stress Student
Description: Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med-Stress Student
Description: Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
Study: NCT05142553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine HIPRA
Description: Subjects will receive one injection of COVID-19 Vaccine HIPRA

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cominarty (Pfizer-BioNtech)
Description: Subjects will receive one injection of Cominarty Vaccine
Study: NCT05932225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol solution/drops
Description: commercially available eye drops
Study: NCT06149208

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Families will complete interviews about their experiences with the new treatment standard and managing pain at home

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Families will complete interviews about their experiences with the new treatment standard and managing pain at home
Study: NCT05484115

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system
Description: treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system
Description: treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
Study: NCT04975776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Description: The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
Study: NCT06027788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CardioGard Embolic Protection Cannula
Description: The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Aortic Cannula
Description: An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
Study: NCT04975776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
Study: NCT04967196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given via DoseConnect device or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given via DoseConnect device or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Assessment
Description: Undergo lymphatic imaging with ICG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Assessment
Description: Undergo lymphatic imaging with ICG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05182840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: Film-coated tablets
Study: NCT05431478

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution
Study: NCT05192993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual motor integration group
Description: Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handwriting intervention programs
Description: (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual motor integration program and Handwriting intervention programs
Description: Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
Study: NCT05661279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia plus Rhomboid intercostal block
Description: the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
Study: NCT01844336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE system 1.1 + CT100 (active treatment)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBASE system 1.1 + CT100 (placebo treatment)
Study: NCT06129136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nature-based exposure by biodiversity component in lotion.
Description: Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group using colored lotion.
Description: Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
Study: NCT05182840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 690517
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin
Study: NCT05676112

Intervention type: DRUG
Intervention: nintedanib
Description: nintedanib
Study: NCT05182840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to empagliflozin
Description: Placebo to empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to empagliflozin
Description: Placebo to empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to empagliflozin
Description: Placebo to empagliflozin
Study: NCT05676112

Intervention type: DRUG
Intervention: pirfenidone
Description: pirfenidone
Study: NCT05182840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to empagliflozin
Description: Placebo to empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to empagliflozin
Description: Placebo to empagliflozin
Study: NCT06396208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)
Description: Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)
Description: Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle